Celldex Therapeutics Inc.
CLDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.16B
Close$
$0.06
99.8% downside
Current Fair Value
99.8% downsideOvervalued by 99.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.16 Billion |
|---|---|
| Enterprise Value | $2.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.9 |
| Beta | 0.9 |
| Outstanding Shares | 77,840,000 |
Return
| Return on Equity | -42.07% |
|---|---|
| Return on Assets | -38.42% |
| Return on Invested Capital | -20.58% |
Valuation & Multiples
| P/E Ratio | -6.31 |
|---|---|
| PEG | -21.14 |
| Price to Sales | - |
| Price to Book Ratio | 3.37 |
| Enterprise Value to Revenue | 18922.92 |
| Enterprise Value to EBIT | -14.28 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.06
Average shareholder expectationRevenue Estimate
$734,917
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$722,636
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 192.81% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.55%▼ 108.53% |
|---|---|
| Total Invested | $38.93M▼ 98.78% |
| Investors Holding | 17▼ 253.00% |
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...